

References

- 1- Jarvis WR, Edwards JR, Culver DH. (1991);
Nasocomial infection rates in adult and
pediatric intensive care units in the united
states;
*Am J Med.*91:185s-91s.
- 2- Bone RC. (1992);
The pathogenesis of sepsis;
*Ann Intern Med.*115:457-69.
- 3- Hazinski MF, Iberti TJ, Macintyre NR.
(1993);
Pathophysiology and clinical presentaion of
gram-negative sepsis;
*Am J Crit Care.*2:224-35.
- 4- Friedman G, Silva E, Vincent JL. (1998);
Has the mortality of septic shock changed
with time?
Crit Care Med. 26:2078-86.
- 5- Noursadeghi M, Cohen J.(2003);
Immunopathogenesis of severe sepsis;
*J R Coll physician Lond.*34:432-6.
- 6- Kollef MH, Schuster DP. (1995);
The acute respiratory distress syndrome;
*New Engel J Med.*332:27-37.

- 7- Thijs A, Thijs LG.(1998);
Pathogenesis of renal failure in sepsis;
*Kidney Int.*53:s34-s37.
- 8- Turner JR, Rill BK, Carlson SL. (1997);
Physiological regulation of epithelial tight
junctions is associated with myosin light-
chain phosphorylation;
*Am J Physiol.*273:c1378-c1385.
- 9- Grocott-Masson MR,shah AM.(1998);
Cardiac dysfunction in sepsis: new theories
and clinical implications;
*Intensive Care Med.*24:286-95.
- 10- Karima R, Matsumoto S, Hidemitsu H,
Matsushima K. (1999);
The molecular pathogenesis of endotoxic
shock and organ failure;
*Mol Med Today.*98:123 33.
- 11- Maekawa T,Fujii Y,sadamitsu D.(1991);
Cerebral circulation and metabolism in
patients with septic encephalopathy;
*Am J Emerg Med.*9:139-43.
- 12- Wheeler AP,Bernard GR.(1999);
Treating patients with severe sepsis;
*New Engl J Med.*340:207-14.
- 13- Vincent J.(1997);
New therapies in sepsis;
*Chest.*112:330s-8s.

14- Salvo I, de Cian W, Mussico M, et al.(1995);
the italian sepsis study: preliminary results
on the incidence and evolution of SIRS,
sepsis;
*Intensive Care Med.*21:s244-9.

15- McCuskey RS, Urbaschek R, Urbaschek B.(1996);
The microcirculation during endotoxemia;
*Cardiol Res.*1317:84-94.

16- Hack CE,Aarden LA, ThijsLG.(1997);
Role of cytokines in sepsis;
*Adv Immunol.*66:101-95.

17- Koj A.(1996);
Initiation of acute phase response and
synthesis of cytokines;
*Biochim Biophys Acta.*1317:752-63.

18- Standiford TJ, Stricter RM, Lukacs NW,
Kunkel SL.(1995);
Neutralization of IL-10 increases lethality in
endotoxemia;
*J Immunol.*155:2222-9.

19- Moss M, Gillespie MK, Ackerson L, Moore
FA, Moore EE, Parsons PE.(1996);
Endothelial cell activity varies in patients at
risk for the adult respiratory distress
syndrome;
*Crit Care Med.*24:1782-6.

20- Fujishima S, Aikawa N.(1995);
Neutrophil-mediated tissue injury and its modulation;

*Intensive Care Med.*21:277-85.

21- Bochner BS.(2000);
Road signs guiding leukocytes along the inflammation superhighway;

*J Allergy Clin Immunol.*106:817-28.

22- Mavrommatis AC, Theodoridis T, Orfanidou A, et al.(2000);
Coagulation system and platelets are fully activated in uncomplicated sepsis;

*Crit Care Med.*28:451-7.

23- Grover R, Lopez A, Lorente J.(1999);
Multi-center, randomized, placebo-controlled, double blind study of thenitric oxide synthase inhibitor effect on survival in patients with septic shock;

*Crit Care Med.*27:A33.

24- Mahidhara R, Billiar TR.(2000);
Apoptosis in sepsis;

*Crit Care Med.*28:N105-N113.

25-Henri clot,Howard Corwin.(2005);
Acute respiratory distress syndrome;

Pulmonology channel.(coated from internet)

26- Landry DW, Levin HR, Gallant EM, et al.(1997);

Vasopressin deficiency contributes to the vasodilation of septic shock;

Circulation.95:1122-5.

27- Jardin F, Fourme T, Page B, et al.(1999);

Persistent preload defect in severe sepsis despite fluid loading: a longitudinal echocardiographic study in patients with septic shock;

Chest.116:1354-9.

28- Hoffmann JN, Werdan K, Harti WH, et al.(1999);

Hemofiltrate from patients with severe sepsis and depressed left ventricular contractility contains cardiotoxic compounds;

Shock.12:174-80.

29- Mariano F, Guida G, Donati D, et al.(1999);

Production of platelet-activating factor in patients with sepsis-associated acute renal failure;

Nephrol Dial Transpl.14:1150-7.

30- Fisher RL, Pipkin GA, Wood JR.(1995);

Stress-related mucosal disease. Pathophysiology, prevention and treatment;

Crit care clin.11:323-45.

31- Unno N, Baba S, Fink MP.(1998);
Cytosolic ionized Ca^{2+} modulates chemical
hypoxia-induced hyperpermeability in
intestinal epithelial monolayers;
*Am J Physiol.*274:G700-G708.

32- Papadopoulos M, Davies DC, Moss RF,
Tighe D, Bennett ED.(2000);
Pathophysiology of septic encephalopathy;
*Crit Care Med.*28:3019-24.

33- Hund EF, Fogel W, Krieger D, DeGeorgia
M, Hacke W.(1996);
Critical illness polyneuropathy: clinical
findings and outcomes of a frequent cause of
neuromuscular weaning failure;
*Crit Care Med.*24:1328-33.

34- Hund E.(1999);
Myopathy in critically ill patients;
*Crit Care Med.*27:2544-7.

35- Slotman GJ, Quinn JV.(1997);
Multivariate regression modeling for the
prediction of inflammation, systemic pressure,
and end organ function in severe sepsis;
*Shock.*8:225-31.

36- Poderoso JJ, Can-eras MC, Lisdero C.(1996);

Nitric oxide inhibits electron transfer and increases superoxide radical production in rat mitochondria and submitochondrial particles;
*Arch Biochem Biophys.*328:85-92.

37- Baudo F, Caimi TM. deCataldo F.(1998);
Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study;

*Intensive Care Med.*24:336-42.

38- Marik PE.ZalogaGP.(1999);
Hypothermia and cytokines in septic shock;

*Intensive Care Med.*26:716-21.

39- Muller B, Becker KL, Schachinger H, et al.(2000);

Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit;

*Crit Care Med.*28:977-83.

40- PovoasP,AlmeidaE, Moreira P, et al.(1998);
C-reactive protein as an indicator of sepsis;

*Intensive Care Med.*24:1052-6.

41-Article by Lewis J Kaplan.(2004);
systemic inflammatory response syndrome;

*eMedicine.*p3:p4.

42- Henri clot, Howard Corwin.(2005);
Acute respiratory distress syndrome;
Pulmonology channel.(coated from internet)

43- Pearson ML.(1996);
Guidelines for the prevention of intravascular
device related infections;
Infect Control Hosp Epidemiol.17:438-73.

44- Leibovici L, Paul M, Poznanski O, et
al.(1997);
Monotherapy versus beta-lactam-
aminoglycoside combination treatment for
gram-negative bacteremia: a prospective,
observational study;
Antimicrob Agents Chemother.41:1127-33.

45- Marik PE.(1998);
Failure of once-daily vancomycin for
staphylococcal endocarditis;
Pharmacotherapy.18:650-2.

46- Marik PE.(2001);
The assessment of intravascular volume: a
comedy of errors;
Crit Care Med.in press.

47- Boldt J, Mueller M, Menges T, Papsdorf M,
Hempelmann G.(1996);
Influence of different volume therapy regimens
on regulators of the circulation in the critically
ill patients;
Br J Anaesth.77:480-7.

48- Schortgen F, Laccherade JC, Bruneel F, et al.(2001);

Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomized study;

Lancet 357:911-6.

49- Ernest D, Belzberg AS, Dodek PM.(1999);

Distribution of normal saline and 5% albumin infusions in septic patient;

Crit Care Med. 27:46-50.

50- Rackow EC, Astiz ME.(1991);

Pathophysiology and treatment of septic shock;

JAMA. 266:548-54.

51- Hollenberg SM, Ahrens TS, Astiz ME, et al.(1999);

Practice parameters for hemodynamic support of sepsis in adult patients in sepsis;

Crit Care Med. 27:639-60.

52- Rohr O, Sawaya BE, Lecestre D, Aunis D, Schaeffer E.(1999);

Dopamine stimulates expression of the human immunodeficiency virus type I via NF-kappaB in cells of the immune system;

Nucleic Acids Res. 27:3291-9.

53- Bersten AD, Rutten AJ.(1999);

Renovascular interaction of epinephrine, dopamine, and intraperitoneal sepsis;

Crit Care Med. 23:537-44.

54- Neviere R, Mathieu D, Chagnon JL, Lebleu N, Wattel F.(1996);

The contrasting effects of dobutamine and dopamine on gastric mucosal perfusion in septic patients;

*Am J Respir Crit Care Med.*154:1684-8.

55- Flancbaum L, Dick M, Dasta J, Choban P.(1997);

A dose-response study of phenylephrine in critically ill, septic surgical patients;

*Eur J Clin Pharmacol.*51:461-5.

56- Raid IA.(1997);

Role of vasopressin deficiency in the vasodilation of septic shock;

*Circulation.*95:1108-10.

57- Lefering R, Neugebauer EAM.(1995);

Steroid controversy in sepsis and septic shock: a meta-analysis;

*Crit Care Med.*23:1294-303.

58- Angus DC, Birmingham MC, Balk RA, et al.(2000);

E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators;

*JAMA.*283:1723-30.

59- Liu M, Slutsky AS.(1997);
Anti-inflammatory therapies: application of
molecular biology techniques in intensive care
medicine;

*Intensive Care Med.*23:718-31.

60- Baudo F, Caimi TM, de Cataldo F, et
al.(1998);

Antithrombin III (ATIII) replacement therapy in
patients with sepsis and/or postsurgical
complications: a controlled double-blind,
randomized, multicenter study;

*Intensive Care Med.*24:336-42.

61- Bernard GR,Vincent JL,Laterre PF,et
ai.(2001);

efficacy and safety of recombinant human
activated protein-c for sever sepsis;

*N Engl J Med.*344:699-709.

62- Biemond BJ, Levi M, ten Cate H, et
al.(2000);

Complete inhibition of endotoxin-induced
coagulation activation in chimpanzees with a
monoclonal Fab fragment against factor
VII/VIIa;

*Thromb haemost.*73:223-30.

63- Busund R, Straume B, Revhaug A.(1993);
Fatal course in severe meningococcemia:
clinical predictors and effects of transfusion
therapy;

*Crit Care Med.*21:1699-705.

64-Article by Lewis J Kaplan.(2004);
systemic inflammatory response syndrome;
eMedicine.p5.